Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.
1. A monoclonal antibody, wherein the antibody is non-naturally occurring and binds tau in normal human brain tissue, but does not bind phosphorylated tau in human Alzheimer's disease (“AD”) brain tissue, wherein the antibody is selected from the group consisting of
a) an antibody comprising a heavy chain CDR1 region of SEQ ID NO:201, a heavy chain CDR2 region comprising SEQ ID NO:202, and a heavy chain CDR3 region comprising SEQ ID NO:203, a light chain CDR1 region comprising SEQ ID NO:204, a light chain CDR2 region comprising SEQ ID NO:205 and a light chain CDR3 region comprising SEQ ID NO:206,
b) an antibody comprising a heavy chain CDR1 region comprising SEQ ID NO:207, a heavy chain CDR2 region comprising SEQ ID NO:208, and a heavy chain CDR3 region comprising SEQ ID NO:209, a light chain CDR1 region comprising SEQ ID NO:210, a light chain CDR2 region comprising SEQ ID NO:211 and a light chain CDR3 region comprising SEQ ID NO:212,
c) an antibody comprising a heavy chain CDR1 region comprising SEQ ID NO:222, a heavy chain CDR2 region comprising SEQ ID NO:223, and a heavy chain CDR3 region comprising SEQ ID NO:224, a light chain CDR1 region comprising SEQ ID NO:225, a light chain CDR2 region comprising SEQ ID NO:173 and a light chain CDR3 region comprising SEQ ID NO:226;
d) an antibody comprising a heavy chain CDR1 region comprising SEQ ID NO:238, a heavy chain CDR2 region comprising SEQ ID NO: 239, and a heavy chain CDR3 region comprising SEQ ID NO:240, a light chain CDR1 region comprising SEQ ID NO:241, a light chain CDR2 region comprising SEQ ID NO:173 and a light chain CDR3 region comprising SEQ ID NO:242,
e) an antibody comprising a heavy chain CDR1 region comprising SEQ ID NO:243, a heavy chain CDR2 region comprising SEQ ID NO:244, and a heavy chain CDR3 region comprising SEQ ID NO:245, a light chain CDR1 region comprising SEQ ID NO:246, a light chain CDR2 region comprising SEQ ID NO: 173 and a light chain CDR3 region comprising SEQ ID NO:212,
f) an antibody comprising a heavy chain CDR1 region comprising SEQ ID NO:243, a heavy chain CDR2 region comprising SEQ ID NO:247, and a heavy chain CDR3 region comprising SEQ ID NO:248, a light chain CDR1 region comprising SEQ ID NO:249, a light chain CDR2 region comprising SEQ ID NO:173 and a light chain CDR3 region comprising SEQ ID NO:212, and
g) an antibody comprising a heavy chain CDR1 region comprising SEQ ID NO:250, a heavy chain CDR2 region comprising SEQ ID NO:251, and a heavy chain CDR3 region comprising SEQ ID NO:252, a light chain CDR1 region comprising SEQ ID NO:254, a light chain CDR2 region comprising SEQ ID NO:254 and a light chain CDR3 region comprising SEQ ID NO:255.
2. The antibody of claim 1 , wherein the antibody forms an immunological complex with tau in normal human brain tissue, but does not form an immunological complex with phosphorylated tau in human AD brain tissue.
3. The antibody according to claim 1 , wherein the antibody comprises:
an antigen binding variable region from a human antibody that binds specifically to tau, and
a recombinant constant region of a human IgG1,
wherein the antibody is different than the human antibody.
4. The antibody according to claim 1 , wherein the antibody comprises:
an antigen binding variable region from a human antibody that binds specifically to tau, and
a recombinant constant region of a human IgG1,
wherein the constant region of the antibody differs from the constant region of the human antibody.
5. The antibody according to claim 1 , wherein the antibody comprises:
a naturally occurring human antigen binding variable region that binds specifically to tau, and
a recombinant constant region of a human IgG1 antibody.
6. The antibody according to claim 1 , wherein the antibody comprises:
naturally occurring human light and heavy chain variable regions from a human antibody, and
recombinant human IgG1 heavy and light chain constant regions.
7. The antibody according to claim 1 , wherein the antibody comprises:
heavy and light chain variable regions from a naturally occurring human antibody, and
recombinant human IgG1 heavy and light chain constant regions.
8. The antibody according to claim 1 , wherein the antibody comprises:
heavy and light chain variable regions from a human antibody, and
recombinant human IgG1 heavy and light chain constant regions.
9. The antibody according to claim 1 , wherein the antibody is a variant of a human monoclonal antibody.
10. The antibody according to claim 1 , wherein the antibody binds to dephosphorylated tau deposits in human AD brain tissue.
11. The antibody of claim 10 , wherein the antibody forms an immunological complex with the dephosphorylated tau deposits in phosphatase-treated human AD brain tissue.
12. The antibody of claim 1 , wherein the antibody binds denatured paired helical filament (“PHF”)-tau, but does not bind non-denatured PHF-tau.
13. The antibody of claim 1 , wherein the antibody binds paired helical filament (“PHF”)-tau by Western blot, but does not bind phosphorylated PHF-tau by ELISA.
14. The antibody of claim 13 , wherein the antibody binds dephosphorylated PHF-tau by ELISA.
15. The antibody of claim 1 , wherein the monoclonal antibody binds to a peptide selected from the group consisting of SEQ ID NO:325 and SEQ ID NO:331.
16. The antibody of claim 15 , wherein the antibody binds to a peptide selected from the group consisting of SEQ ID NO:382, SEQ ID NO:458 and SEQ ID NO:386.
17. An immunoconjugate comprising:
the antibody of claim 1 or an antigen-binding fragment thereof, and
at least one therapeutic agent and/or detectable agent associated therewith.
18. An isolated nucleic acid molecule encoding the antibody of claim 1 or an antigen-binding fragment thereof.
19. A vector comprising the nucleic acid molecule according to claim 18 .
20. A host cell comprising the vector according to claim 19 .
21. A method of producing an antibody or an antigen-binding fragment thereof, the method comprising:
culturing the host cell of claim 20 , and
recovering the antibody or fragment thereof produced by the host cell.
22. A pharmaceutical composition comprising:
the antibody of claim 1 or an antigen-binding fragment thereof, and
at least one pharmaceutically acceptable excipient.
23. A kit comprising at least one antibody of claim 1 or an antigen-binding fragment thereof.